| Literature DB >> 35535903 |
An-Qi Zhang1, Lu Wang1, Yi-Xiu Wang2, Shan-Shan Hong1, Yu-Shan Zhong1, Ru-Yi Yu1, Xin-Lu Wu1, Bing-Bing Zhou1, Qi-Min Yu1, Hai-Feng Fu1, Shuang-Dong Chen1, Yun-Chang Mo1, Qin-Xue Dai1, Jun-Lu Wang1.
Abstract
Previous studies have suggested that miR-324-3p is related to the pathophysiology of cerebral ischemia, but the mechanism underlying this relationship is unclear. In this study, we found that miR-324-3p expression was decreased in patients with acute ischemic stroke and in in vitro and in vivo models of ischemic stroke. miR-324-3p agomir potentiated ischemic brain damage in rats subjected to middle cerebral artery occlusion, as indicated by increased infarct volumes and cell apoptosis rates and greater neurological deficits. In a PC12 cell oxygen-glucose deprivation/reoxygenation model, a miR-324-3p mimic decreased cell viability and expression of the anti-apoptotic protein BCL2 and increased expression of the pro-apoptotic protein BAX and rates of cell apoptosis, whereas treatment with a miR-324-3p inhibitor had the opposite effects. Silencing miR-324-3p increased adenosine A1 receptor (A1R) expression through regulation of GATA binding protein 2 (GATA2). These findings suggest that silencing miR-324-3p reduces ischemic brain damage via the GATA2/A1R axis.Entities:
Keywords: GATA2; PC12 cells; acute ischemic stroke; adenosine A1 receptor; apoptosis; cerebral ischemia-reperfusion injury; cortical neurons; miR-324-3p; middle cerebral artery occlusion; oxygen-glucose deprivation/reoxygenation
Year: 2022 PMID: 35535903 PMCID: PMC9120691 DOI: 10.4103/1673-5374.339009
Source DB: PubMed Journal: Neural Regen Res ISSN: 1673-5374 Impact factor: 6.058
Baseline characteristics of the included participant
| Variable | AIS ( | Control ( | |
|---|---|---|---|
| Sex | 0.355 | ||
| Male | 10 (55.6) | 5 (38.5) | |
| Female | 8 (44.4) | 8 (61.5) | |
| Age (yr) | 65 (54–76) | 58 (53–67) | 0.002 |
| Height (cm) | 165.4 (159.5–171.3) | 163.5 (157–167) | 0.435 |
| Weight (kg) | 65.75±13.45 | 57.87±8.72 | 0.138 |
| BMI (kg/m2) | 24.08±4.88 | 21.71±2.67 | 0.109 |
| Smoking | 6 (33.3) | 3 (23.1) | 0.361 |
| Drinking | 4 (22.2) | 3 (23.1) | 0.361 |
| Hypertension | 13 (72.2) | 3 (23.1) | 0.018 |
| Diabetes | 5 (27.8) | 1 (7.7) | 0.169 |
Data are expressed as number (percentage), mean ± SD or median (interquartile range) as appropriate. AIS: Acute ischemic stroke; BMI: body mass index.
Cell grouping in the in vitro experiment
| Groups | PC12 cells |
|---|---|
| CON | 5 μL sterile water |
| Mimic | 50 nM miR-324-3p mimic |
| Mimic NC | 50 nM miR-324-3p mimic NC |
| Inhibitor | 100 nM miR-324-3p inhibitor |
| Inhibitor NC | 100 nM miR-324-3p inhibitor NC |
| OGD/REP | OGD/REP |
| OGD/REP mimic | 50 nM miR-324-3p mimic+OGD/REP |
| OGD/REP mimic NC | 50 nM miR-324-3p mimic NC+OGD/REP |
| OGD/REP inhibitor | 100 nM miR-324-3p inhibitor+OGD/REP |
| OGD/REP inhibitor NC | 100 nM miR-324-3p inhibitor NC+OGD/REP |
| OGD/REP inhibitor + GATA2 siRNA | 100 nM miR-324-3p inhibitor NC+OGD/REP+20 μM GATA2 siRNA |
GATA2: GATA binding protein 2; NC: normal control; OGD/REP: oxygen-glucose deprivation/reoxygenation.
The primer sequences used in quantitative reverse transcription-polymerase chain reaction in this study
| Gene (accession number) | Primer sequence (5’–3’) |
|---|---|
|
| |
| miR-324-3P (100314181) | F: ACC CAC TGC CCC AGG TGC |
| R: ATC CAG TGC AGG GTC CGA GG | |
| RT primer: GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACC AGG GG | |
| U6 (reference gene) | F: cgcgcgcgAGA GAA GAT TAG CAT GG |
| R: ATC CAG TGC AGG GTC CGA GG | |
| RT primer: GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACC AGG GG | |
| A1R (29290) | F: CCT ACA TCT CGG CCT TCC AG |
| R: GTG CCT GGT TCA CCT TCA CA | |
| GATA2 (25159) | F: AAG GAT GGC GTC AAG TATC AAG TGT C |
| R: AGC TGA GGC AGG CAC ATA GGA G | |
| BCL2 (24224) | F: CAC GGT GGT GGA GGA ACT CT |
| R: CAC GGT GGT GGA GGA ACT CT | |
| BAX (24887) | F: GGC GAT GAA CTG GAC AAC AA |
| R: GGC GAT GAA CTG GAC AAC AA | |
| GAPDH (24383) | F: GAC ATG CCG CCT GGA GAA AC |
| R: AGC CCA GGA TGC CCT TTA GT | |
|
| |
| miR-324-3P (442898) | F: CCC ACT GCC CCA GGT GC |
| R: CCC ACT GCC CCA GGT GC | |
| RT primer: 5′CCC ACT GCC CCA GGT GC | |
| U6 (reference gene) | F: AGA GAA GAT TAG CAT GGC CCC TG |
| R: AGA GAA GAT TAG CAT GGC CCC TG | |
| RT primer: GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACA AAA TA |
A1R: Adenosine A1 receptor; GATA2: GATA binding protein 2.